Homocysteine levels are associated with the results of 123I- metaiodobenzylguanidine myocardial scintigraphy in type 2 diabetic patients

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 1, 2007, Pages 28-35

  Anan, Futoshi ^a   Yonemochi, Hidetoshi ^a   Masaki, Takayuki ^b   Takahashi, Naohiko ^b   Nakagawa, Mikiko ^a   Eshima, Nobuoki ^a   Saikawa, Tetsunori ^a   Yoshimatsu, Hironobu ^b  

^a OITA UNIVERSITY   (Japan)

^b OITA UNIVERSITY   (Japan)

Author keywords

123I metaiodobenzylguanidine scintigraphy; Baroreflex sensitivity; Endothelial dysfunction; Homocysteine; Insulin resistance

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; IODINE 123; METAIODOBENZYLGUANIDINE I 123; NORADRENALIN; PIOGLITAZONE; SULFONYLUREA;

ADULT; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG UPTAKE; FEMALE; HEART RATE VARIABILITY; HEART SCINTISCANNING; HUMAN; HYPERHOMOCYSTEINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORADRENALIN BLOOD LEVEL; PRESSORECEPTOR REFLEX;

3-IODOBENZYLGUANIDINE; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS;

EID: 33845366742     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0200-9     Document Type: Article

References (43)

1. Nygard O, Nordrehaug JE, Refsum H, Ureland PM, farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-236
2. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 2002;325:1202-1206
3. Tsuji H, Larson MG, Venditti FJ Jr, Manders ES, Evans JC, Feldman CL, et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Study. Circulation 1996;94:2850-2855
4. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infraction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infraction) Investigators. Lancet 1998;351:478-484
5. Reichard P, Pihl M. Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes 1994;43:313-317
6. Takahashi N, Nakagawa M, Saikawa T, Ooie T, Yufu K, Shigematsu S, et al. Effect of essential hypertension on cardiac autonomic function in type 2 diabetic patients. J Am Coll Cardiol 2001;38:232-237
7. Takahashi N, Anan F, Nakagawa M, Yufu K, Ooie T, Nawata T, et al. Microalbuminuria, cardiovascular autonomic dysfunction, and insulin resistance in patients with type 2 diabetes mellitus. Metabolism 2004;53:1359-1364
8. Anan F, Takahashi N, Ooie T, Nakagawa M, Saikawa T, Yoshimatsu H. High-sensitivity C-reactive protein is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients. Metabolism 2005;54:552-558
9. Giltay EJ, Hoogeveen EK, Elbers JM, Gooren LJ, Asscheman H, Stehouwer CD. Insulin resistance is associated with elevated plasma homocysteine levels in healthy, non-obese subjects. Arteriosclerosis 1998;139:197-198
10. Emoto M, Kanda H, Shoji T, Kawagishi T, Komatsu M, Mori K, et al. Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. Diabetes Care 2001;24:533-538
11. Gerritsen J, TenVoorde BJ, Dekker JM, Kingma R, Kostense PJ, Bouter LM, et al. Measures of cardiovascular autonomic dysfunction nervous function: agreement, reproducibility, and reference values in middle age and elderly subjects. Diabetologia 2003;46:330-338
12. 123I-MIBG. J Nucl Med 1999;40:6-11
13. Spallone V, Menzinger G. Diagnosis of cardiovascular autonomic neuropathy in diabetes. Diabetes 1997;46:S67-S76
14. Watanabe K, Sekiya M, Tsuruoka T, Funada J, Kameoka H, Miyagawa M, et al. Relationship between insulin resisatnce and cardiac sympathetic nervous function in essential hypertension. J Hypertens 1999;17:1161-1168
15. Liao D, Sloan RP, Cascio WE, Folsom AR, Liese AD, Evans GW, et al. Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. Diabetes Care 1998;21:2116-2122
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419
17. Donnelly JG, Pronovost C. Evaluation of the Abbott IMx fluorescence polarization immunoassay and the Bio-Rad enzyme immunoassay for homocysteine: comparison with high-performance liquid chromatography. Ann Clin Biochem 2000;37:194-198
18. Davies L, Wilmshurst EG, McElduff A, Gunton J, Clifton-Bligh P, Fulcher GR. The relationship among homocysteine, creatinine clearance, and albuminuria in patients with type 2 diabetes. Diabetes Care 2001;24:1805-1809
19. Sato T, Nishinaga M, Kawamoto A, Ozawa T, Takatsuji H. Accuracy of a continuous blood pressure monitor based on arterial tonometry. Hypertension 1993;21:866-874
20. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996;98:5-7
21. Tirosh A, Potashnik R, Bashan N, Rudich A. Oxidant stress disrupts insulin-induced redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. A putative cellular mechanism for impaired protein kinase B activation and glut4 translocation. J Biol Chem 1999;274:10595-10602
22. Najib S, Sanchez-Margalet V. Homocysteine thiolactone inhibits insulin signaling and glutathione has a protective effects. J Mol Endocrinol 2001;27:85-91
23. Jacobs RL, House JD, Brosnan ME, Brosnan JT. Effects of treptozotocin-induced diabetes and insulin treatment on homocysteine metabolism rat. Diabetes 1998;47:1967-1970
24. Fonseca V, Dicker-Brown A, Ranganathan S, Song W, Barnard RJ, Fink L, et al. Effects of a high-fat-sucrose diet on enzymes in homocysteine metabolism in the rat. Metabolism 2000;49:736-741
25. Ambrosch A, Dierkes J, Lobmann R, Kuhne W, Konig W, Luley C, et al. Relation between homocysteinaemia and diabetic neuropathy in patients with type 2 diabetes mellitus. Diabetic Med 2001;174:185-192
26. Cohen JA, Jeffers BW, Stabler S, Schrier RW, Estascio R. Increasing homocysteine levels and diabetic autonomic neuropathy. Auton Neurosci 2001;87:268-273
27. Spoelstra-De Man AM, Smulders YM, Dekker JM, Heine RJ, Bouter LM, Nijpels G, et al. Homocysteine levels are not associated with cardiovascular autonomic function in elderly Caucasian subjects without or with type 2 diabetes mellitus: Hoorn study. J Intern Med 2005;258:536-543
28. 123I] metaiodobenzylguanidine. Diabetes 1992;41:1069-1075
29. Schnell O, Muhr D, Weiss M, Kirsch CM, Haslbeck M, Tatsch K, et al. Three-year follow-up on scintigraphically assessed cardiac sympathetic denervation in patients with long-term insulin-dependent (type I) diabetes mellitus. J Diabetes Complicat 1997;11:307-313
30. Weir DG, Scott JM. The biochemical basis of neuropathy in cobalamin deficiency. Bailliere's Clin Heamatol 1995;8:479-497
31. Chowdhary S, Vaile JC, Fletcher J, Ross HF, Coote JH, Townend JN. Nitric oxide and cardiac autonomic control in humans. Hypertension 2000;36:264-269
32. Davis JI, Band M, Morris A, Struthers AD. Spironolactone impaires endothelial dysfunction and heart rate variability in patients with type 2 diabetic. Diabetologia 2004;47:1687-1694
33. Meigs J, Jacques P, Selhub J, Singer D, Nathan D, Rifai N, et al. Fasting plasma homocysteine levels in the insulin resistance syndrome. The Framingham Offspring study. Diabetes Care 2001;24:1403-1410
34. Wheeler DC, Townend JN, Landray MJ. Cardiovascular risk factors in predialysis patients: baseline data from the Chronic Renal Impairment in Birmingham (CRIB) study. Kidney Int Suppl 2003;84:S201-S203
35. Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, et al. Elevated fasting total plasma homocyateine levels and cardiovascular disease outcomes in maintenance dialysis patients: a prospective study. Arterioscler Thromb Vasc Biol 1997;17:2554-2558
36. Davies L, Wilmshurst EG, Mcelduff A, Gunton J, Clifton-Bligh P, Fulcher GR. The relationship among homocysteine, creatinine clearance, and albuminuria in patients with type 2 diabetes. Diabetes Care 2001;24:1805-1809
37. Gavras HP. Issues in hypertension: drug tolerability and special populations. Am J Hypertens 2001;14(Pt 2):231S-236S
38. Lender D, Arauz-Pacheco C, Breen L, Mora-Mora P, Ramirez LC, Raskin P. A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens 1999;12:298-303
39. Kontopoulos AG, Athyros VG, Didangelos TP, Papageorgiou AA, Avramidis MJ, Mayroudi MC, et al. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care 1997;20:355-361
40. Rodgers JE, Patterson JH. Angiotensin II-receptor blockers: clinical relevance and therapeutic role. Am J Health Syst Pharm 2001;58:671-683
41. Lefrandt JD, Heitmann J, Sevre K, Castelloano M, Hausberg M, Fallon M, et al. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study. Am J Hypertens 2001;14:1083-1089
42. Yamashina S, Yamazaki J. Role of MIBG myocardial scintigraphy in the assessment of heart failure: the need to establish evidence. Eur J Nucl Med Mol Imaging 2004;31:1353-1355
43. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart faiure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2005;45:661-667